Dr. Reddy's Laboratories
118 hedge funds and large institutions have $814M invested in Dr. Reddy's Laboratories in 2017 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 42 increasing their positions, 41 reducing their positions, and 22 closing their positions.
2% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 41
7.7% less ownership
Funds ownership: 76.25% → 68.55% (-7.7%)
8% less funds holding
Funds holding: 128 → 118 (-10)
24% less capital invested
Capital invested by funds: $1.07B → $814M (-$251M)
41% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 22
71% less call options, than puts
Call options by funds: $1.95M | Put options by funds: $6.6M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$12.1M |
| 2 |
BlackRock
New York
|
+$6.77M |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$5.51M |
| 4 |
Jane Street
New York
|
+$3.77M |
| 5 |
Citigroup
New York
|
+$3.56M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CBOA
Commonwealth Bank of Australia
Sydney, NSW,
Australia
|
-$48.4M |
| 2 |
AQR Capital Management
Greenwich,
Connecticut
|
-$22.5M |
| 3 |
HSBC Holdings
London,
United Kingdom
|
-$10.2M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$7.71M |
| 5 |
LP
LMR Partners
London,
United Kingdom
|
-$7.48M |
RDY Hedge Fund Activity: Q3 2017 in Review
118 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Dr. Reddy's Laboratories (RDY) for Q3 2017, worth a combined $814M — down 24% from $1.07B a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of RDY and 13 opened new positions — a net loss of 9 holders — while 41 trimmed existing stakes and 42 added.
The largest buyer was UBS Group, adding an estimated $12.1M. The largest seller was Commonwealth Bank of Australia, cutting an estimated $48.4M.
- 118 institutional investors held Dr. Reddy's Laboratories (RDY) as of Q3 2017, down from 128 in Q2 2017.
- Funds reported $814M of Dr. Reddy's Laboratories stock for Q3 2017, down 24% quarter-over-quarter.
- 13 funds opened new Dr. Reddy's Laboratories positions in Q3 2017 and 22 closed out, a net change of -9 holders.
- The largest Dr. Reddy's Laboratories buyer in Q3 2017 was UBS Group, an estimated $12.1M added.
- The largest Dr. Reddy's Laboratories seller in Q3 2017 was Commonwealth Bank of Australia, an estimated $48.4M sold.
Based on aggregated 13F filings for Q3 2017.